Carol Lynch, president of Sandoz US and head of North America, discusses the barriers blocking market access for biosimilars in the United States.
Transcript:
What are some barriers that are blocking market access to biosimilars in the United States?
Well, in order to be able to commercialize a product, first of all, you need to get regulatory approval, and I think we’re doing pretty okay there. If you look at the number of approvals in the [United States], it’s definitely catching up. Still behind Europe, but definitely catching up. Then you need to be able to launch.
If you look at the number of approvals, which today is 17, and yet only 5 of those products are actually being marketed today. So clearly, we’ve got an issue once we’ve had approvals to get to market, and I think that’s where the litigation barriers come in.
Then, once on market, if you look at the performance of the various products that have been launched, then you see quite an inconsistency.
Our own Zarzio was launched more than 3 years ago and has performed, I think, according to expectations of a biosimilar in a developed market. We have achieved leading market share by volume within 3 years of launch, overtaking the originator, so I would say that is a successful biosimilar. But we don’t necessarily see that across all of the brands that have been launched. So, I think there’s still some inconsistency there, and one of the major barriers is actually around the contracting and rebating practices we see from some of the originator companies.
So clearly, still a number of barriers to be taken down in order to have a vibrant biosimilar healthcare system in the [United States].
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.